The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1250 articles
The Wegovy pill, the first oral medication for weight loss in adults, might be available in Canada if approved by health officials. The medication has already been approved in the U.S. and has shown promising results in clinical trials.
Allison Rankin recounts her experience of discomfort and vomiting after overeating at a family Christmas dinner while taking Mounjaro. Doctors caution against overeating on weight loss drugs due to slowed digestion.
Weight loss medications such as Ozempic and Wegovy function by artificially elevating glucagon-like peptide 1 (GLP-1), a naturally occurring hormone that combats obesity and diabetes. Research indicates that certain foods can boost GLP-1 secretion, offering similar benefits without injections. These foods not only increase GLP-1 but also mimic its effects, aiding in weight management and overall health.
The Food and Drug Administration (FDA) has given the green light to Novo Nordisk's oral Wegovy pill, a semaglutide medication, for weight loss management. This new option offers an alternative to injectable medications for individuals struggling with obesity or overweight conditions. Clinical trials have demonstrated significant weight loss results.
Novo Nordisk recently announced that the FDA has approved its GLP-1 anti-obesity drug, Wegovy, in pill form. This new oral version provides a convenient alternative to injections for weight loss in adults with obesity or weight-related health issues.
Jim Cramer commented on Eli Lilly's GLP-1 pill, anticipating a revolutionary impact. He also assessed other portfolio holdings, including Taiwan Semi, Chevron, SL Green, and Microsoft, providing insights into their respective sectors.
Amanda Bynes, the former actress, recently disclosed a 28-pound weight loss achieved with Ozempic. She expressed her motivation and shared a recent photo on Instagram. Bynes has been open about her past struggles and journey toward self-acceptance.
As we approach 2026, agrifoodtech founders are closely monitoring significant trends. From the influence of GLP-1 drugs on consumer choices to the transformative potential of AI and continuous fermentation, these innovations are set to reshape the industry.
Shares of Zydus Lifesciences Limited garnered attention this morning after a High Court ruling authorized the company to produce semaglutide for export to specific nations. The stock saw movement, reflecting investor response to the news.
